Top Insights
Health
globalreutersAugust 12, 20241 Mins read
Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency
globalreutersAugust 12, 20241 Mins read 
FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. But competition could come from others, including an AstraZeneca peptide in late-stage development.
The post Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency appeared first on MedCity News.
Related Articles
How Should Healthcare Startups Approach Employers? 3 Execs Weigh In
During a panel at the MedCity News INVEST Digital Health conference, three...
As Medicaid Unwinding Concludes in Most States, KFF Finds 25 Million Lost Medicaid Coverage but Enrollment is 10 Million Higher Than Pre-Pandemic Levels
Over 25 million people were disenrolled from Medicaid and over 56 million...
Cultural Competence in Medical Tourism
Cultural sensitivity is a key factor when treating visitors from other nations...
Reporting Checklist for Discrete Choice Experiments in Health
What are the key elements for reporting your objective, attributes, experimental design,...
Leave a comment